Comparison of Acuseal and Standard ePTFE Vascular Grafts for Hemodialysis: A Retrospective Case Series

Grafts, which allow early cannulation have been increasingly used to avoid starting dialysis via tunneled hemodialysis catheters. As we noted graft failures in patients with early cannulation grafts, we reviewed the outcome of these grafts and compared it to ePTFE grafts. We retrospectively analyzed time to first intervention, primary and secondary patency rates as well as the number of interventions needed to maintain patency in patients who received an early cannulation graft (GORE® ACUSEAL, acuseal) or an ePTFE (GORE-TEX®) vascular graft between January 2016 and November 2017 in our medical center. 12 patients who had received an acuseal vascular graft were compared with 13 patients with an ePTFE vascular graft. The mean time to first intervention was similar in both groups. On average 0.33 interventions per graft were needed per month to maintain patency in the acuseal group, and 0.08 in the ePTFE group (p = 0.02). The primary patency rate did not differ significantly between the groups. The secondary patency rate at the end of the observation period was significantly worse in the acuseal group (p = 0.02). Four acuseal grafts were lost after a mean of 202 days, whereas none of the ePTFE grafts was lost. Our data is consistent with our clinical impression of an increased number of interventions and lower longevity of the acuseal vascular graft. These data need conformation in a larger cohort.

[1]  N. Inston,et al.  Early cannulation grafts for haemodialysis: An updated systematic review , 2018, The journal of vascular access.

[2]  M. Glickman Early Cannulation Graft: Acuseal , 2016, The journal of vascular access.

[3]  W. C. Sternbergh,et al.  Heparin-Bonded Polytetrafluorethylene Does Not Improve Hemodialysis Arteriovenous Graft Function. , 2016, Annals of vascular surgery.

[4]  H. Schanzer,et al.  Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis. , 2015, Journal of vascular surgery.

[5]  O. Olsha,et al.  A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access. , 2015, Journal of vascular surgery.

[6]  G. Piffaretti,et al.  Initial Experience with the Gore® Acuseal Graft for Prosthetic Vascular Access , 2014, The journal of vascular access.

[7]  D. Kingsmore,et al.  Early Cannulation Prosthetic Graft (Acuseal™) for Arteriovenous Access: A useful option to provide a Personal Vascular access Solution , 2014, The journal of vascular access.

[8]  V. Kashyap,et al.  Heparin bonding does not improve patency of polytetrafluoroethylene arteriovenous grafts. , 2014, Annals of vascular surgery.

[9]  E. Gillaspie,et al.  Early Cannulation Prosthetic Graft (Flixene™) for Arteriovenous Access , 2011, The journal of vascular access.

[10]  Jürgen Reichling,et al.  An Updated Systematic Review of the Pharmacology of Silymarin , 2007, Complementary Medicine Research.

[11]  Randy L Carter,et al.  Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. , 2003, Journal of vascular surgery.

[12]  W. McClellan,et al.  Vascular access and increased risk of death among hemodialysis patients. , 2002, Kidney international.